免疫检查点抑制剂与银屑病风险
该全国性队列研究采用目标试验模拟设计,基于台湾健康保险数据库和癌症登记库,纳入2019年1月1日至2021年6月30日期间接受抗癌药物治疗的III、IV期癌症患者。结果显示,ICI使用者银屑病发病率为5.76例/1000人年,高于非ICI使用者的1.44例/1000人年;经IPTW调整后,ICI使用者银屑病风险增加约2倍(IPTW调整HR 3.31;IPTW调整亚分布HR 2.43)。
要点
- ICI使用者银屑病发病率5.76例/1000人年,非ICI使用者1.44例/1000人年。
- IPTW调整后ICI使用者银屑病风险增加约2倍(HR 3.31;亚分布HR 2.43)。
- 临床应警惕免疫治疗相关银屑病,以保障最佳肿瘤诊疗。
核心结论
- 在接受ICI治疗的癌症患者中,银屑病风险升高。
研究设计与样本
- 全国性队列研究,采用目标试验模拟设计,数据来自台湾健康保险数据库和台湾癌症登记库。
- 纳入2019年1月1日至2021年6月30日期间接受抗癌药物治疗的III、IV期癌症患者。
主要发现
- ICI使用者银屑病发病率为5.76例/1000人年,非ICI使用者为1.44例/1000人年。
- 调整人口学和合并症后,ICI使用者银屑病风险增加约2倍(IPTW调整HR 3.31;IPTW调整亚分布HR 2.43)。
关键数值与推荐
- 主要结局为随访期间银屑病发病率。
- 采用稳定逆概率治疗加权(IPTW)控制混杂,Cox和Fine-Gray风险模型计算风险比。
临床怎么用
- 医疗专业人员应了解免疫治疗可能引起银屑病等不良反应,确保最佳肿瘤诊疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Immune checkpoint inhibitors (ICIs) are recognized as revolutionary cancer therapies but have raised concerns about immune-related adverse events, including the development of autoimmune diseases. OBJECTIVE: To evaluate the psoriasis risk associated with the use of ICIs in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: This nationwide cohort study with a target trial emulation design used data from the Taiwan National Health Insurance database and the Taiwan Cancer Registry. The participants included were patients who received antineoplastic medications for cancer at stages III and IV between January 1, 2019, and June 30, 2021. Data were analyzed from May 2023 to July 2024. EXPOSURES: Patients treated with ICIs were classified as ICI users, while those who received chemotherapy or targeted therapies were categorized as non-ICI users. MAIN OUTCOME AND MEASURES: The primary outcome was the incidence of psoriasis during the follow-up period. Stabilized inverse probability of treatment weighting (IPTW) was used to mitigate potential confounders. Cox and Fine-Gray hazard models were used to calculate hazard ratios (HRs) for psoriasis risk between groups. RESULTS: Of 135 230 patients who received antineoplastic medications (mean [SD] age, 62.94 [13.01] years; 45.1% female), 3188 patients were eligible for the ICI user group, while 132 042 patients were eligible for the non-ICI user group. ICI users experienced a higher incidence of psoriasis at 5.76 cases per 1000 person-years, compared to 1.44 cases in the non-ICI group. After adjusting for demographics and comorbidities, ICI users were found to have a 2-fold increase in the risk of developing psoriasis (IPTW-adjusted HR, 3.31; IPTW-adjusted subdistribution HR, 2.43). Both as-started design and on-treatment design showed consistent findings, and the results were consistent and robust across all follow-up intervals and all sensitivity analyses. CONCLUSIONS AND RELEVANCE: In this cohort study, patients with cancer treated with ICIs faced an increased risk of psoriasis. Medical professionals should be aware of the potential adverse effects of immunotherapy to ensure optimal cancer care.
引用
- To SY, Lee CH, Chen YH, et al. Psoriasis Risk With Immune Checkpoint Inhibitors. JAMA Dermatol. 2025. PMID: 39504056. doi:10.1001/jamadermatol.2024.4129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。